BOSTON & SYDNEY--(BUSINESS WIRE)--GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited’s engagement to explore options for seeking admission of GI Dynamics shares to trade on the London Stock Exchange’s AIM market.

Allenby Capital is a London-based NOMAD (nominated adviser) and broker on the London Stock Exchange’s AIM market that focuses on providing a range of advisory and transactional services to growing businesses. Allenby Capital has played a leading role in numerous successful listings and secondary fundraisings for its corporate clients in various business sectors and geographical jurisdictions.

“We look forward to working with Allenby Capital to explore options for listing GI Dynamics shares on the AIM market,” said Scott Schorer, GI Dynamics’ President and CEO. “Allenby Capital comes highly recommended and has the relevant experience to fully explore this opportunity. AIM represents an attractive public equity market for international growth companies seeking to access capital. We also view AIM as a method of increasing GI Dynamics profile in our key European markets, which is synchronized with our commercial focus.”

About GI Dynamics

GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. EndoBarrier is approved and commercially available in multiple countries outside the United States. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.